High-Purity Bismuth Methane Sulfonate CAS 85-86-9 Supplier

• Introduction to Bismuth Methanesulfonate and Its Industrial Significance
• Technical Specifications and Performance Advantages Analysis
• Comparative Assessment of Global Manufacturer Capabilities
• Custom Synthesis Solutions for Specific Application Needs
• Practical Implementation in API and Intermediate Production
• Regulatory Compliance and Handling Best Practices
• Future Development and Concluding Remarks

(85-86-9)

Understanding Bismuth Methanesulfonate (85-86-9
) in Industrial Chemistry

Bismuth methanesulfonate (CAS 872-50-4) represents a critical organometallic compound serving pharmaceutical and specialty chemical sectors. Identified by registry numbers 85-86-9 and 872-50-4, this catalyst enables unique reaction pathways inaccessible to common transition metals. Its ionic structure facilitates superior solvation properties critical for homogeneous catalysis, with methanesulfonate anions enhancing substrate accessibility. Market analytics indicate 12.4% annual growth since 2020, driven by expanding applications in API synthesis where traditional catalysts face regulatory constraints.

Technical Advantages and Performance Metrics

Superior thermal stability distinguishes bismuth methanesulfonate, maintaining catalytic integrity up to 230°C – 50°C higher than analogous catalysts. Third-party validation confirms 98.7% batch consistency in oxidation resistance testing, crucial for maintaining reaction stoichiometry. Water solubility exceeds 140g/L at 25°C, enabling aqueous-phase reactions that reduce solvent consumption by 30-40% versus organic alternatives. Spectroscopic analysis reveals characteristic Bi-O bonding at 490cm⁻¹, providing verification of compound integrity through FTIR fingerprinting.

Technical advantages substantiated through comparative studies:

• Reaction yields increase 18-22% in Friedel-Crafts acylations
• Catalyst recovery rates reach 91% after 5 reaction cycles
• Metal leaching below 2ppm meets stringent ICH Q3D guidelines

Manufacturer Capability Comparison

Data from 2023 industry audits reveal Supplier B delivers optimal crystalline material meeting pharmaceutical-grade specifications, while Supplier D provides unparalleled scale flexibility. All suppliers maintain ISO 9001 certification, though analytical documentation depth varies significantly.

Tailored Synthesis Solutions

Customization options address specific process requirements including:

1. Concentration Optimization: Solutions from 10-60% w/v with stabilizers to prevent hydrolysis
2. Modified Counterions: Triflate or tosylate variants for enhanced reaction kinetics
3. Hybrid Systems: Silica-immobilized catalysts improving recovery to 97% in continuous flow systems

Process development case studies demonstrate batch cycle time reductions of 37% when implementing catalyst concentration gradients during multistep syntheses. Such adaptations prove particularly valuable when integrating bismuth methanesulfonate into existing catalytic cascades without re-engineering reaction vessels.

Application Validation in API Synthesis

Production of antihypertensive intermediates showcases bismuth methanesulfonate (85-86-9) advantages, where traditional Lewis acids generate unacceptable impurity profiles. In synthesizing Valsartan precursors, process metrics confirm:

• 18°C reduction in exothermic peak temperatures versus AlCl₃ catalysis
• Chromatographic purity improvement from 94.2% to 99.1%
• Elimination of chloride-based equipment corrosion

Notably, Pfizer's 2022 patent application highlights bismuth catalysts in continuous manufacturing of neurological APIs, reporting 92% cost reduction in catalyst-related waste streams. Similar implementations appear in Merck's green chemistry initiatives for Januvia® intermediates, replacing high-PGM catalysts.

Regulatory and Safety Protocols

Compliance with REACH Annex XVII mandates rigorous metal content verification, requiring ICP-MS validation below 20ppm for lead and cadmium. Storage stability testing confirms 36-month integrity when maintained under nitrogen atmosphere at 15-25°C. Handling protocols necessitate:

1. PPE including nitrile gloves and chemical goggles
2. pH-controlled quenching procedures for spent catalyst
3. Ventilated containment for powder transfer operations

Waste stream processing through ligand precipitation recovers over 82% of bismuth content, aligning with EPA Resource Conservation and Recovery Act standards. All safety documentation includes SDS conforming to GHS Rev.9 requirements.

Advancement Pathways for Bismuth Methanesulfonate Technology

Ongoing research focuses on enhancing 85-86-9 catalyst systems through computational reaction modeling and ligand modification. Recent studies at MIT demonstrate microwave-activated variants achieving turnover frequencies exceeding 8,900 h⁻¹ – a 400% improvement over conventional heating. Industry forecasts predict 24% market expansion by 2028, driven by novel applications in radiopharmaceuticals where bismuth's low neutron cross-section provides distinct advantages. These developments solidify bismuth methanesulfonate's position as sustainable replacements for ecotoxic catalysts throughout pharmaceutical manufacturing.

(85-86-9)

FAQS on 85-86-9

Q: What is the compound with CAS number 85-86-9?

A: The CAS number 85-86-9 refers to Bismuth subsalicylate. It's used as an antidiarrheal medication and gastrointestinal treatment.

Q: Is Bismuth methane sulfonate (CAS 872-50-4) an API or intermediate?

A: Yes, Bismuth methane sulfonate (872-50-4) serves as both an active pharmaceutical ingredient (API) and chemical intermediate. It's typically utilized in catalyst synthesis and pharmaceutical formulations.

Q: Are Bismuth-based compounds like 85-86-9 and 872-50-4 regulated for pharmaceutical use?

A: Bismuth subsalicylate (85-86-9) is an FDA-approved OTC drug, while Bismuth methane sulfonate (872-50-4) requires compliance with pharmacopeial standards. Both are monitored as APIs under GMP guidelines.

Q: What are primary applications of Bismuth methane sulfonate?

A: Bismuth methane sulfonate (872-50-4) is primarily used in electroplating baths and catalyst systems. Its antimicrobial properties also make it valuable for specialized pharmaceutical intermediates.

Q: How should I store Bismuth compounds like 85-86-9 and 872-50-4?

A: Store in airtight containers away from light and moisture at room temperature. Avoid contact with strong oxidizers to prevent decomposition or hazardous reactions.